PT - JOURNAL ARTICLE AU - Asada, Kiyoshi AU - Nakajima, Takeshi AU - Shimazu, Taichi AU - Yamamichi, Nobutake AU - Maekita, Takao AU - Yokoi, Chizu AU - Oda, Ichiro AU - Ando, Takayuki AU - Yoshida, Takeichi AU - Nanjo, Sohachi AU - Fujishiro, Mitsuhiro AU - Gotoda, Takuji AU - Ichinose, Masao AU - Ushijima, Toshikazu TI - Demonstration of the usefulness of epigenetic cancer risk prediction by a multicentre prospective cohort study AID - 10.1136/gutjnl-2014-307094 DP - 2015 Mar 01 TA - Gut PG - 388--396 VI - 64 IP - 3 4099 - http://gut.bmj.com/content/64/3/388.short 4100 - http://gut.bmj.com/content/64/3/388.full SO - Gut2015 Mar 01; 64 AB - Background Epigenetic alterations accumulate in normal-appearing tissues of patients with cancer, producing an epigenetic field defect. Cross-sectional studies show that the degree of the defect may be associated with risk in some types of cancer, especially cancers associated with chronic inflammation. Objective To demonstrate, by a multicentre prospective cohort study, that the risk of metachronous gastric cancer after endoscopic resection (ER) can be predicted by assessment of the epigenetic field defect using methylation levels. Design Patients with early gastric cancer, aged 40–80 years, who planned to have, or had undergone, ER, were enrolled at least 6 months after Helicobacter pylori infection discontinued. Methylation levels of three preselected genes (miR-124a-3, EMX1 and NKX6-1) were measured by quantitative methylation-specific PCR. Patients were followed up annually by endoscopy, and the primary endpoint was defined as detection of a metachronous gastric cancer. Authentic metachronous gastric cancers were defined as cancers excluding those detected within 1 year after the enrolment. Results Among 826 patients enrolled, 782 patients had at least one follow-up, with a median follow-up of 2.97 years. Authentic metachronous gastric cancers developed in 66 patients: 29, 16 and 21 patients at 1–2, 2–3 and ≥3 years after the enrolment, respectively. The highest quartile of the miR-124a-3 methylation level had a significant univariate HR (95% CI) (2.17 (1.07 to 4.41); p=0.032) and a multivariate-adjusted HR (2.30 (1.03 to 5.10); p=0.042) of developing authentic metachronous gastric cancers. Similar trends were seen for EMX1 and NKX6-1. Conclusions Assessment of the degree of an epigenetic field defect is a promising cancer risk marker that takes account of life history.